Sign In
Last checked at 
5 Dec 2019 11:30
genedrive plc
("genedrive" or the "Company")
Additional listing
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that, further to the announcement of the fifth deed of amendment to the Visible Genomics SPA on 16 November 2018, it has issued 869,565 ordinary shares of 1.5p each in the capital of the Company ("VGL Shares") to the shareholder of Visible Genomics Limited. This is to settle the deferred consideration payable on the first anniversary of the date of admission of the shares issued in the placing on which the amendment was conditional. The VGL Shares will be subject to an orderly marketing arrangement.
Application has been made to the London Stock Exchange for the VGL Shares to be admitted to trading on AIM. Admission is expected to be effective on 10 December 2019. The VGL Shares shall rank pari passu with the existing ordinary shares in the Company.
Following admission, the Company's issued share capital will comprise 34,870,071 Ordinary Shares and each Ordinary Share carries one vote. There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 34,870,071. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further details please contact:
genedrive plc | www.genedriveplc.com | |
David Budd: CEO / Matthew Fowler: CFO | +44 (0)161 989 0245 | |
Peel Hunt LLP | +44 (0)20 7418 8900 | |
James Steel / Oliver Jackson | ||
Stanford Capital Partners Limited | +44 (0)20 3815 8880 | |
Patrick Claridge / John Howes | ||
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com | |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).
Follow the stocks
